Skip to main content
. Author manuscript; available in PMC: 2014 Jan 15.
Published in final edited form as: Circulation. 2012 Dec 5;127(2):213–223. doi: 10.1161/CIRCULATIONAHA.112.131110

Figure 1.

Figure 1

Figure 1

Infarct size reduction after hCSC and bone marrow hMSC therapy. Delayed enhancement CMR images showing pre-injection scar and 4-weeks post-injection scar changes (white arrows indicate infarct extension) in (A) combination c-kit+ hCSC/hMSC (n=5), (B) c-kit+ hCSC alone (n=5), (C) hMSC alone (n=5), and (D) placebo (n=5) treated pigs. Reduction in (E) absolute infarct size and (F) infarct size as a percentage of LV mass shows all stem cell treated pigs had reduced infarct size compared to placebo and combination therapy had substantially greater scar size reduction compared to either hMSC alone or hCSC alone. (*p<0.05 and **p<0.0001 within group repeated measures ANOVA; †p<0.05 combination hCSC/hMSC vs. both hCSC alone and hMSC alone between group repeated measures ANOVA; ≠. p=0.02 combination hCSC/hMSC vs. hMSC alone and p=0.06 combination hCSC/hMSC vs hCSC alone between group repeated measures ANOVA; graphs represent mean±SEM)